In 2023, Germany led the European market for Systemic Hormonal Preparations (excluding sex hormones and insulins) with €1.32 billion in sales, followed by Belgium (€0.1311 billion) and Greece (€0.1247 billion). Notable year-on-year growth was recorded in Austria (2.4%) and Germany (2.2%), while Greece saw a decline of 1.27%. Over the last five years, a modest CAGR signifies steady market growth varied by country.
Future trends to watch include potential market expansion driven by technological advancement and regulatory changes. Monitoring innovation in hormone therapy and healthcare reforms will be crucial for understanding market dynamics going forward.
Top countries in Systemic Hormonal Preparations Sales (Excluding Sex Hormones and Insulins) by Country
| # | 6 Countries | Million Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 1,320 | 2023 | +2.04% | +2.2% | View data |
| 2 | 2 Belgium | 131.1 | 2023 | -1.28% | +0.81% | View data |
| 3 | 3 Greece | 124.7 | 2023 | +0.89% | -1.27% | View data |
| 4 | 4 Austria | 66.2 | 2023 | +2.32% | +2.4% | View data |
| 5 | 5 Finland | 48.9 | 2023 | +1.66% | +0.8% | View data |
| 6 | 6 Portugal | 29.9 | 2023 | 0% | +2.14% | View data |
